Retinal Structure and Function in Achromatopsia Implications for Gene Therapy

UCL Institute of Ophthalmology, University College London, London, UK
Ophthalmology (Impact Factor: 6.14). 10/2013; 121(1). DOI: 10.1016/j.ophtha.2013.08.017
Source: PubMed


To characterize retinal structure and function in achromatopsia (ACHM) in preparation for clinical trials of gene therapy.
Cross-sectional study.
Forty subjects with ACHM.
All subjects underwent spectral domain optical coherence tomography (SD-OCT), microperimetry, and molecular genetic testing. Foveal structure on SD-OCT was graded into 5 distinct categories: (1) continuous inner segment ellipsoid (ISe), (2) ISe disruption, (3) ISe absence, (4) presence of a hyporeflective zone (HRZ), and (5) outer retinal atrophy including retinal pigment epithelial loss. Foveal and outer nuclear layer (ONL) thickness was measured and presence of hypoplasia determined.
Photoreceptor appearance on SD-OCT imaging, foveal and ONL thickness, presence of foveal hypoplasia, retinal sensitivity and fixation stability, and association of these parameters with age and genotype.
Forty subjects with a mean age of 24.9 years (range, 6-52 years) were included. Disease-causing variants were found in CNGA3 (n = 18), CNGB3 (n = 15), GNAT2 (n = 4), and PDE6C (n = 1). No variants were found in 2 individuals. In all, 22.5% of subjects had a continuous ISe layer at the fovea, 27.5% had ISe disruption, 20% had an absent ISe layer, 22.5% had an HRZ, and 7.5% had outer retinal atrophy. No significant differences in age (P = 0.77), mean retinal sensitivity (P = 0.21), or fixation stability (P = 0.34) across the 5 SD-OCT categories were evident. No correlation was found between age and foveal thickness (P = 0.84) or between age and foveal ONL thickness (P = 0.12).
The lack of a clear association of disruption of retinal structure or function in ACHM with age suggests that the window of opportunity for intervention by gene therapy is wider in some individuals than previously indicated. Therefore, the potential benefit for a given subject is likely to be better predicted by specific measurement of photoreceptor structure rather than simply by age. The ability to directly assess cone photoreceptor preservation with SD-OCT and/or adaptive optics imaging is likely to prove invaluable in selecting subjects for future trials and measuring the trials' impact.
The authors have no proprietary or commercial interest in any of the materials discussed in this article.

Download full-text


Available from: Michel Michaelides, Jan 03, 2014
  • Source

    Ophthalmology 04/2014; DOI:10.1016/j.ophtha.2014.03.008 · 6.14 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To describe the imaging characteristics and to investigate the prognostic factors of acute retinal pigment epitheliitis. Methods: In this retrospective observational case series, a total of 18 patients (18 eyes) with acute retinal pigment epitheliitis were included. The features of acute retinal pigment epitheliitis were analyzed by spectral-domain optical coherence tomography (SD-OCT). Results: Spectral domain-OCT images obtained at baseline revealed abnormal reflectivity in the RPE inner layer in every case (18 eyes, 100%). The line corresponding to the RPE inner layer, the inner segment ellipsoid (ISe), showed abnormal reflectivity in 16 cases (89%). Among patients with ISe abnormalities, three eyes (17%) also showed external limiting membrane (ELM) disruption and two expanded abnormal reflectivity in the outer nuclear layer (ONL). With time, SD-OCT images showed disappearance and gradual resolution of the ONL hyperreflectivity, and disruption of the ELM or ISe. Sixteen eyes (89%) fully recovered their BCVA within 2 months. However, two eyes (11%) with involvement of the ELM or ONL at baseline, with BCVA of less than 20/70 at baseline, showed incomplete BCVA recovery after more than 1 year of follow-up. Conclusions: Spectral domain-OCT findings indicated that the initial lesion in acute retinal pigment epitheliitis is located at the junction between the photoreceptor outer segments and the apical sides of the RPE cells. Poor visual acuity at baseline and involvement of the ELM or ONL on SD-OCT at baseline were associated with the incomplete recovery of visual acuity.
    Investigative Ophthalmology &amp Visual Science 05/2014; 55(5):3314-3319. DOI:10.1167/iovs.14-14324 · 3.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary cone disorders (CDs) are characterized by defects of the cone photoreceptors or retinal pigment epithelium underlying the macula, and include achromatopsia (ACHM), cone dystrophy (COD), cone-rod dystrophy (CRD), color vision impairment, Stargardt disease (STGD) and other maculopathies. Forty-two genes have been implicated in non-syndromic inherited CDs. Mutations in the 5 genes implicated in ACHM explain ∼93% of the cases. On the contrary, only 21% of CRDs (17 genes) and 25% of CODs (8 genes) have been elucidated. The fact that the large majority of COD and CRD-associated genes are yet to be discovered hints towards the existence of unknown cone-specific or cone-sensitive processes. The ACHM-associated genes encode proteins that fulfill crucial roles in the cone phototransduction cascade, which is the most frequently compromised (10 genes) process in CDs. Another 7 CD-associated proteins are required for transport processes towards or through the connecting cilium. The remaining CD-associated proteins are involved in cell membrane morphogenesis and maintenance, synaptic transduction, and the retinoid cycle. Further novel genes are likely to be identified in the near future by combining large-scale DNA sequencing and transcriptomics technologies. For 31 of 42 CD-associated genes, mammalian models are available, 14 of which have successfully been used for gene augmentation studies. However, gene augmentation for CDs should ideally be developed in large mammalian models with cone-rich areas, which are currently available for only 11 CD genes. Future research will aim to elucidate the remaining causative genes, identify the molecular mechanisms of CD, and develop novel therapies aimed at preventing vision loss in individuals with CD in the future.
    Progress in Retinal and Eye Research 05/2014; 42. DOI:10.1016/j.preteyeres.2014.05.001 · 8.73 Impact Factor
Show more